Ginkgo Bioworks Holdings

DNA on NYSE. Ginkgo Bioworks Holdings sells cell engineering and biosecurity services to government and commercial customers. Market value $795m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.

Capital spending looks too small to be complete, so we leave free cash flow out.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
n/a

We could not compute this from the filings.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 20 of 100. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.

$12.41 a share, 131% above its 1-year low

Over the past year the price has ranged from $5.37 to $18.22.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.3
-0.3
-0.3
-0.4
n/a
20212022202320242025
Revenue
$314m$478m$251m$227m$170m
Operating margin
-582.6%-462.4%-343.8%-246.5%-185.3%
Debt to equity
n/an/an/an/an/a
Shares outstanding
1.61bn1.89bn0.05bn0.05bn0.06bn

Health checks

  • Free cash flow positive0 of 4 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)1 of 7 checks we could run
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsShrinking, 14.2% a year
  • Buying back its own sharesYes, 96% fewer since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $20 million last quarter, down 48% on a year ago.
  • A loss of $47 million, compared with a loss of $60 million a year ago.
  • It loses 260 cents on each $1 of sales, compared with 142 cents a year earlier.
  • Sales did not grow on a year ago in any of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$89m
December 2024$44m
March 2025$38m
June 2025$39m
September 2025$39m
December 2025$33m
March 2026$19m
June 2026$20m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$56m
December 2024-$108m
March 2025-$91m
June 2025-$60m
September 2025-$81m
December 2025-$81m
March 2026-$83m
June 2026-$47m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
26 February 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 184 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

5 investors own more than 5%.

  • Reshma P. Shetty
    Insider or founder
    at least 9.5%
    (filed with 1 related holder)
    Since 14 February 2025
  • BlackRock, Inc.
    Passive investor
    7.7%+1.2 pts
    Since 30 June 2026
  • Cascade Investment, L.L.C.
    Passive investor
    at least 7.5%
    (filed with 1 related holder)
    Since 30 September 2025
  • Viking Global Investors
    Passive investor
    at least 7.1%
    (filed with 6 related holders)
    Since 31 March 2026
  • Austin Che
    Passive investor
    5.0%
    Since 31 December 2024
  • BAILLIE GIFFORD & CO
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026
  • Sold down below 5%
    Since 30 September 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 4 sold $3m.

  • HENRY CHRISTIAN O
    Director
    Sold
    Date
    15 September 2026
    Shares
    5,000
    Price
    $7.08
    Value
    $35,405
  • Coen Steven P.
    See remarks
    Sold
    Date
    24 August 2026
    Shares
    330
    Price
    $6.98
    Value
    $2,302
  • Coen Steven P.
    See remarks
    Sold
    Date
    17 July 2026
    Shares
    752
    Price
    $7.90
    Value
    $5,943
  • Coen Steven P.
    See remarks
    Sold
    Date
    22 May 2026
    Shares
    307
    Price
    $8.33
    Value
    $2,557
  • Coen Steven P.
    See remarks
    Sold
    Date
    17 April 2026
    Shares
    324
    Price
    $7.95
    Value
    $2,576
  • Coen Steven P.
    See remarks
    Sold
    Date
    13 April 2026
    Shares
    33,171
    Price
    $6.41
    Value
    $212,626
  • Shetty Reshma P.
    See remarks, Director
    Sold
    Date
    10 April 2026
    Shares
    124,727
    Price
    $6.43
    Value
    $801,995
  • Shetty Reshma P.
    See remarks, Director
    Sold
    Date
    9 April 2026
    Shares
    13,116
    Price
    $6.40
    Value
    $83,942
  • Kelly Jason R
    See remarks, Director
    Sold
    Date
    9 April 2026
    Shares
    109,767
    Price
    $6.40
    Value
    $702,509
  • Shetty Reshma P.
    See remarks, Director
    Sold
    Date
    8 April 2026
    Shares
    13,155
    Price
    $6.93
    Value
    $91,164

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Feb 2026, plus the 10-Q filed 6 Aug 2026 and 6 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • Sales have shrunk: 14.2% a year.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.